ZyversaREV_cmyk.jpg
ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Attend JPM’s Healthcare Conference 2025 in San Francisco
18. Dezember 2024 07:55 ET | ZyVersa Therapeutics
ZyVersa looks forward to meeting with investors and potential collaborators at JPM 2025 to discuss our technology, pipeline, and development milestones.
ZyversaREV_cmyk.jpg
ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinical Trial
20. November 2024 07:55 ET | ZyVersa Therapeutics
Stroke-related cardiovascular injury and dysfunction are induced by AIM2 inflammasome activation in the heart, which can be blocked by ZyVersa's IC 100.
ZyversaREV_cmyk.jpg
ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update
14. November 2024 08:10 ET | ZyVersa Therapeutics
ZyVersa announces progress toward achieving key near-term development milestones and Q3-2024 financials.
ZyversaREV_cmyk.jpg
ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic Islet Beta Cells and Attenuate Progression from Obesity to Insulin Resistance and Type 2 Diabetes
05. November 2024 07:00 ET | ZyVersa Therapeutics
Inflammasome-driven inflammation in obesity results in severely damaged pancreatic islets, leading to islet cell loss and metabolic dysfunction.
ZyversaREV_cmyk.jpg
ZyVersa Therapeutics Highlights Review Article Supporting the Need for Drug Therapies to Treat the Inflammation of Obesity in Addition to Weight Loss Drugs
29. Oktober 2024 07:57 ET | ZyVersa Therapeutics
Obesity treatment needs to go beyond weight loss and address the damaging inflammation leading to life-altering comorbidities.
ZyversaREV_cmyk.jpg
ZyVersa Therapeutics Highlights Published Data Demonstrating That Obesity Results in Neuroinflammation Implicated in Development of Neurodegenerative Diseases
22. Oktober 2024 07:57 ET | ZyVersa Therapeutics
Newly published data show that obesity leads to progressive brain inflammation that worsens with prolonged obesity and increased age.
ZyversaREV_cmyk.jpg
ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Highlighting Obesity Development Plans for Inflammasome ASC Inhibitor IC 100 Over the Next Nine Months
17. Oktober 2024 07:50 ET | ZyVersa Therapeutics
It is anticipated that Inflammasome ASC Inhibitor IC 100 will control chronic inflammation of obesity, attenuate comorbidities, and enhance weight loss.
ZyversaREV_cmyk.jpg
ZyVersa Therapeutics CEO, Stephen C. Glover, Was a Featured Guest on The Big Biz Show to Discuss Current Trends in the Obesity Drug Market and the Potential Role of Inflammasome Inhibitors
15. Oktober 2024 07:50 ET | ZyVersa Therapeutics
ZyVersa discusses trend toward add-on therapy for obesity to address metabolic complications and the role of inflammasome inhibitors on Big Biz Show.
ZyversaREV_cmyk.jpg
ZyVersa Therapeutics Forms New Scientific Advisory Board to Support Development of Inflammasome ASC Inhibitor IC 100 for Obesity with Metabolic Complications
07. Oktober 2024 07:55 ET | ZyVersa Therapeutics
ZyVersa Therapeutics forms new obesity, metabolic and inflammatory disease Scientific Advisory Board.
ZyversaREV_cmyk.jpg
ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business Update
09. August 2024 16:40 ET | ZyVersa Therapeutics
KEY HIGHLIGHTS Phase 2a clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease on track to begin H2-2024.Obesity with related metabolic complications...